Chargement en cours...
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)
We conducted a study of combined treatment with docetaxel, bevacizumab, and everolimus in patients with chemotherapy-naive metastatic castrate-resistant prostate cancer. Although we establish a safe dose for coadministration of these 3 agents and our early results suggested encouraging levels of ant...
Enregistré dans:
| Publié dans: | Clin Genitourin Cancer |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444943/ https://ncbi.nlm.nih.gov/pubmed/28826933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.07.003 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|